Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

首次发布于 2017 年 2 月 28 日

RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.

计划入组 376 人 · 首次发布于 2017 年 12 月 18 日

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

计划入组 52 人 · 首次发布于 2024 年 7 月 30 日

NTRK1 inhibitor(Mochida Pharmaceutical)

NTRK1 gene inhibitor (Sangamo/Diamyd)

ERAS-2/3

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Geneseeq's PanTRKare™ Receives NMPA Approval as China's First NGS-Based Pan-Solid Tumor Companion Diagnostic for NTRK Gene Fusions

Tempus Study Shows Concurrent RNA and DNA Sequencing Improves Actionable Variant Detection in NSCLC

Biomarker Testing Crucial for Personalized Treatment in Metastatic NSCLC, Experts Emphasize